Karyopharm Cash from 2010 to 2024

KPTI Stock  USD 1.12  0.02  1.75%   
Karyopharm Therapeutics' Cash is increasing with slightly volatile movements from year to year. Cash is estimated to finish at about 101.7 M this year. Cash is the total amount of money in the form of currency that Karyopharm Therapeutics has in its possession. This includes all bills, coins, and funds in bank accounts. View All Fundamentals
 
Cash  
First Reported
2011-12-31
Previous Quarter
52.9 M
Current Value
31.1 M
Quarterly Volatility
53.2 M
 
Yuan Drop
 
Covid
Check Karyopharm Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Karyopharm main balance sheet or income statement drivers, such as Depreciation And Amortization of 503.5 K, Interest Expense of 25 M or Selling General Administrative of 67.5 M, as well as many exotic indicators such as Price To Sales Ratio of 0.64, Dividend Yield of 0.0 or Days Sales Outstanding of 52.74. Karyopharm financial statements analysis is a perfect complement when working with Karyopharm Therapeutics Valuation or Volatility modules.
  
This module can also supplement Karyopharm Therapeutics' financial leverage analysis and stock options assessment as well as various Karyopharm Therapeutics Technical models . Check out the analysis of Karyopharm Therapeutics Correlation against competitors.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.

Latest Karyopharm Therapeutics' Cash Growth Pattern

Below is the plot of the Cash of Karyopharm Therapeutics over the last few years. Cash refers to the most liquid asset of Karyopharm Therapeutics, which is listed under current asset account on Karyopharm Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Karyopharm Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Karyopharm Therapeutics account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Karyopharm Therapeutics' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Karyopharm Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Cash10 Years Trend
Slightly volatile
   Cash   
       Timeline  

Karyopharm Cash Regression Statistics

Arithmetic Mean87,336,338
Geometric Mean47,490,084
Coefficient Of Variation67.68
Mean Deviation49,259,827
Median85,918,000
Standard Deviation59,111,790
Sample Variance3494.2T
Range190.1M
R-Value0.48
Mean Square Error2900.6T
R-Squared0.23
Significance0.07
Slope6,327,709
Total Sum of Squares48918.9T

Karyopharm Cash History

2024101.7 M
202352.9 M
2022135.2 M
2021190.5 M
202085.9 M
2019128.9 M
2018118 M

Other Fundumenentals of Karyopharm Therapeutics

Karyopharm Therapeutics Cash component correlations

About Karyopharm Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Karyopharm Therapeutics income statement, its balance sheet, and the statement of cash flows. Karyopharm Therapeutics investors use historical funamental indicators, such as Karyopharm Therapeutics's Cash, to determine how well the company is positioned to perform in the future. Although Karyopharm Therapeutics investors may use each financial statement separately, they are all related. The changes in Karyopharm Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Karyopharm Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Karyopharm Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Karyopharm Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

Currently Active Assets on Macroaxis

When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:
Check out the analysis of Karyopharm Therapeutics Correlation against competitors.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for Karyopharm Stock analysis

When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Commodity Directory
Find actively traded commodities issued by global exchanges
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Stocks Directory
Find actively traded stocks across global markets
Global Correlations
Find global opportunities by holding instruments from different markets
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Is Karyopharm Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.27)
Revenue Per Share
1.224
Quarterly Revenue Growth
(0.14)
Return On Assets
(0.31)
Return On Equity
(8.91)
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.